Sergi Mas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergi Mas has a total of 553 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Gassó
Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
83 shared publications - Miquel Bernardo
Ciber de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
49 shared publications Amalia Lafuente
Universitat de Barcelona
36 shared publications- Natalia Rodríguez
Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
33 shared publications - Amalia Lafuente
Dep. Farmacología y Química Terapéutica, Universidad de Barcelona, IDIBAPS, Casanova 143, E-08036 Barcelona, Spain
24 shared publications - Eduard Parellada
Barcelona Clínic Schizophrenia Unit (BCSU), Institute of Neuroscience, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain
18 shared publications
Latest Publications
- 2 September 2026
- Published by Elsevier in Psychiatry Research
- Vol. 366
Cognitive profiles in first-episode psychosis: The impact of genetics, environment, and cognitive reserve as risk and protective factors
- 2 September 2026
- Published by Elsevier in Psychiatry Research
- Vol. 366
Cognitive profiles in first-episode psychosis: The impact of genetics, environment, and cognitive reserve as risk and protective factors
- Open Access
- 10 August 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- p. 1-13
Polygenic profiles in youth with early-onset psychosis and offspring of schizophrenia or bipolar disorder patients
The role of genetic factors shaping liability for psychosis remains unclear. Youth with first-episode, early-onset psychosis and youth at increased familial risk for psychosis show higher rates of co-occurring psychiatric diagnoses and cognitive difficulties than the general population. This study assessed polygenic scores (PGS) for psychiatric diagnoses, cognition and educational attainment in 414 youth: N = 69 cases with non-affective, early-onset psychosis (schizophrenia, schizophreniform and schizoaffective disorders), N = 62 cases with affective, early-onset psychoses (bipolar or depressive disorders with psychotic symptoms), N = 52 offspring of patients with schizophrenia, N = 94 offspring of patients with bipolar disorder, and N = 117 healthy controls. After quality control, PGS were calculated using the PRS-CS tool. Differences in PGS were examined by fitting binary logistic models. Sensitivity analyses ruled out effects of potential confounders. PGS for schizophrenia and bipolar disorder were higher in youth with non-affective, early-onset psychoses and offspring of patients with schizophrenia, and higher PGS scores for attention deficit hyperactivity disorder (ADHD) were found in youth with non-affective, early-onset psychoses and offspring of patients with bipolar disorder, relative to controls. PGS for cognition and educational attainment were lower in youth with non-affective, early-onset psychoses, compared with youth with affective, early-onset psychoses, offspring of bipolar disorder patients, and controls (all P FDR <0.05). Conclusion: These findings indicate shared and distinct genetic liability profiles influenced by patient and parental diagnoses. In addition to liability for schizophrenia and bipolar disorder, polygenic profiles for ADHD, cognition, and educational attainment may determine the genetic architecture of psychosis.
- 10 August 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- p. 1-13
Open AccessPolygenic profiles in youth with early-onset psychosis and offspring of schizophrenia or bipolar disorder patients
The role of genetic factors shaping liability for psychosis remains unclear. Youth with first-episode, early-onset psychosis and youth at increased familial risk for psychosis show higher rates of co-occurring psychiatric diagnoses and cognitive difficulties than the general population. This study assessed polygenic scores (PGS) for psychiatric diagnoses, cognition and educational attainment in 414 youth: N = 69 cases with non-affective, early-onset psychosis (schizophrenia, schizophreniform and schizoaffective disorders), N = 62 cases with affective, early-onset psychoses (bipolar or depressive disorders with psychotic symptoms), N = 52 offspring of patients with schizophrenia, N = 94 offspring of patients with bipolar disorder, and N = 117 healthy controls. After quality control, PGS were calculated using the PRS-CS tool. Differences in PGS were examined by fitting binary logistic models. Sensitivity analyses ruled out effects of potential confounders. PGS for schizophrenia and bipolar disorder were higher in youth with non-affective, early-onset psychoses and offspring of patients with schizophrenia, and higher PGS scores for attention deficit hyperactivity disorder (ADHD) were found in youth with non-affective, early-onset psychoses and offspring of patients with bipolar disorder, relative to controls. PGS for cognition and educational attainment were lower in youth with non-affective, early-onset psychoses, compared with youth with affective, early-onset psychoses, offspring of bipolar disorder patients, and controls (all P FDR <0.05). Conclusion: These findings indicate shared and distinct genetic liability profiles influenced by patient and parental diagnoses. In addition to liability for schizophrenia and bipolar disorder, polygenic profiles for ADHD, cognition, and educational attainment may determine the genetic architecture of psychosis.
- Open Access
- 23 May 2026
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 26 (1)
Clustering longitudinal data: comparison of model-based and distance-based approaches using simulated and real-world data in psychiatric research
Clustering longitudinal symptom trajectories is increasingly used to characterise clinical heterogeneity in psychiatric disorders. However, the relative performance of distance-based and model-based approaches remains insufficiently studied in psychiatric settings, where limited follow-up waves, measurement variability, and heterogeneous patient responses may affect clustering reliability. We aimed to systematically compare distance-based and model-based (Latent Class Mixed Models, LCMMs) methods, evaluating their performance in recovering the number of groups, classification accuracy, and clinical interpretability. We analysed longitudinal symptom data from 237 first-episode psychosis patients (PEPs cohort). We also performed simulations (500 replicates per scenario) with known group structures (3 or 4), varying group-size distributions (balanced/unbalanced) and levels of group separation (well-separated, partially overlapping, strongly overlapping). Recovery of the true or optimal number of groups was assessed using multiple validity indices. Classification accuracy was measured by weighted Cohen's [Formula: see text]. Clinical interpretability was evaluated in terms of within-group homogeneity, stability across replications, and minimum group size. In the PEPs cohort, distance-based methods consistently identified two stable and clinically interpretable trajectory groups, whereas LCMMs frequently suggested more complex structures, often including very small classes. Concordance between methodological families was low, indicating that patient stratification was strongly method-dependent: distance-based methods grouped patients primarily by overall symptom severity, whereas LCMMs distinguished groups according to trajectory slope. In simulations, both approaches performed well when groups were clearly separated, but performance declined with increasing overlap and group-size imbalance. Distance-based methods generally produced more stable and homogeneous partitions, whereas LCMMs showed greater variability across replications. In psychiatric longitudinal studies with few assessment waves and moderate sample sizes, distance-based clustering methods may provide a robust strategy for trajectory-based partitioning. Model-based approaches such as LCMMs may offer advantages when complex nonlinear trajectories are expected, but their stability may be limited under noisy or weakly separated conditions. Combining multiple evaluation criteria and considering clinical interpretability are essential for reliable subgroup identification.
- 23 May 2026
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 26 (1)
Open AccessClustering longitudinal data: comparison of model-based and distance-based approaches using simulated and real-world data in psychiatric research
Clustering longitudinal symptom trajectories is increasingly used to characterise clinical heterogeneity in psychiatric disorders. However, the relative performance of distance-based and model-based approaches remains insufficiently studied in psychiatric settings, where limited follow-up waves, measurement variability, and heterogeneous patient responses may affect clustering reliability. We aimed to systematically compare distance-based and model-based (Latent Class Mixed Models, LCMMs) methods, evaluating their performance in recovering the number of groups, classification accuracy, and clinical interpretability. We analysed longitudinal symptom data from 237 first-episode psychosis patients (PEPs cohort). We also performed simulations (500 replicates per scenario) with known group structures (3 or 4), varying group-size distributions (balanced/unbalanced) and levels of group separation (well-separated, partially overlapping, strongly overlapping). Recovery of the true or optimal number of groups was assessed using multiple validity indices. Classification accuracy was measured by weighted Cohen's [Formula: see text]. Clinical interpretability was evaluated in terms of within-group homogeneity, stability across replications, and minimum group size. In the PEPs cohort, distance-based methods consistently identified two stable and clinically interpretable trajectory groups, whereas LCMMs frequently suggested more complex structures, often including very small classes. Concordance between methodological families was low, indicating that patient stratification was strongly method-dependent: distance-based methods grouped patients primarily by overall symptom severity, whereas LCMMs distinguished groups according to trajectory slope. In simulations, both approaches performed well when groups were clearly separated, but performance declined with increasing overlap and group-size imbalance. Distance-based methods generally produced more stable and homogeneous partitions, whereas LCMMs showed greater variability across replications. In psychiatric longitudinal studies with few assessment waves and moderate sample sizes, distance-based clustering methods may provide a robust strategy for trajectory-based partitioning. Model-based approaches such as LCMMs may offer advantages when complex nonlinear trajectories are expected, but their stability may be limited under noisy or weakly separated conditions. Combining multiple evaluation criteria and considering clinical interpretability are essential for reliable subgroup identification.
- Open Access
- 27 April 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e114
Cognitive reserve in non-affective first-episode psychosis: contributions of polygenic scores, early clinical features, and environment
Background: Cognitive reserve (CR) is a protective factor in first-episode psychosis (FEP), influencing cognitive, clinical, and functional outcomes. CR is shaped by a combination of genetic, clinical, and environmental factors, yet the extent of their respective contributions remains unclear. This study investigates the influence of polygenic risk scores (PRS), clinical and environmental variables on CR in FEP. Methods: A cohort of 174 individuals with non-affective FEP, aged 25.5 (SD=5.3), was analyzed. CR was assessed using a socio-behavioral proxy. PRS for educational attainment (PRS EA ), intelligence (PRS IQ ), cognitive performance (PRS CP ), occupational attainment (PRS OA ), physical activity (PRS PA ), and schizophrenia (PRS SZ ) were calculated. Age at onset, socioeconomic status, birth weight, and family history of psychosis were considered. Multiple regression models were employed to evaluate the impact of the different predictors on CR. Results: PRS EA (p=0.002), age at onset (p=5.32x10 -5 ), and family history of psychosis (p=0.001) emerged as the strongest contributors to CR. Higher PRS EA was associated with higher levels of CR, while earlier age at onset and positive family history were associated with lower CR. The model incorporating environmental, clinical, and genetic variables explained 17.7% of the variance in CR, and the one without PRS explained 13.5%. The inclusion of PRS EA in the model improved the explanatory power (Δadj.R 2 =0.042) and predictive accuracy (ΔRMSE=−0.288). Conclusions: These findings highlight the role of precision psychiatry in better understanding CR. Early identification of individuals with earlier onset, family history of psychosis, and lower genetic predisposition to educational attainment may help characterize those with lower CR.
- 27 April 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e114
Open AccessCognitive reserve in non-affective first-episode psychosis: contributions of polygenic scores, early clinical features, and environment
Background: Cognitive reserve (CR) is a protective factor in first-episode psychosis (FEP), influencing cognitive, clinical, and functional outcomes. CR is shaped by a combination of genetic, clinical, and environmental factors, yet the extent of their respective contributions remains unclear. This study investigates the influence of polygenic risk scores (PRS), clinical and environmental variables on CR in FEP. Methods: A cohort of 174 individuals with non-affective FEP, aged 25.5 (SD=5.3), was analyzed. CR was assessed using a socio-behavioral proxy. PRS for educational attainment (PRS EA ), intelligence (PRS IQ ), cognitive performance (PRS CP ), occupational attainment (PRS OA ), physical activity (PRS PA ), and schizophrenia (PRS SZ ) were calculated. Age at onset, socioeconomic status, birth weight, and family history of psychosis were considered. Multiple regression models were employed to evaluate the impact of the different predictors on CR. Results: PRS EA (p=0.002), age at onset (p=5.32x10 -5 ), and family history of psychosis (p=0.001) emerged as the strongest contributors to CR. Higher PRS EA was associated with higher levels of CR, while earlier age at onset and positive family history were associated with lower CR. The model incorporating environmental, clinical, and genetic variables explained 17.7% of the variance in CR, and the one without PRS explained 13.5%. The inclusion of PRS EA in the model improved the explanatory power (Δadj.R 2 =0.042) and predictive accuracy (ΔRMSE=−0.288). Conclusions: These findings highlight the role of precision psychiatry in better understanding CR. Early identification of individuals with earlier onset, family history of psychosis, and lower genetic predisposition to educational attainment may help characterize those with lower CR.
- Open Access
- 12 April 2026
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 108, 112834
Corrigendum to “Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls” [European Neuropsychopharmacology 81 (2024) 28–37]
- 12 April 2026
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 108, 112834
Open AccessCorrigendum to “Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls” [European Neuropsychopharmacology 81 (2024) 28–37]
- Open Access
- 23 March 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-12
Predicting early clinical recovery in first-episode psychosis: development and external validation of a clinically interpretable multivariable model
Background: Identifying patients with first-episode psychosis (FEP) who are unlikely to achieve early clinical recovery (ECR) is critical for personalised intervention and resource allocation. ECR – defined as the concurrent achievement of symptomatic and functional remission – represents a clinically meaningful outcome that captures both illness control and functional reintegration. Aims: To develop and externally validate prediction models for ECR using clinical, cognitive and genetic data. Method: We analysed two large, independent Spanish cohorts: the primeros episodios psicóticos cohort ( N = 335), for model development and internal validation, and the Programa Asistencial a las Fases Iniciales de Psicosis cohort ( N = 668), for external validation. Forty-seven baseline clinical and cognitive variables and 87 polygenic risk scores (PRSs) were examined. Predictors were selected using penalised logistic regression. Logistic regression and three machine learning algorithms were compared for discrimination, calibration and clinical utility. Results: The best-performing model was a logistic regression using six routinely collected clinical and cognitive predictors (duration of untreated psychosis, days of treated psychosis, baseline functioning, insight, executive function and cognitive reserve), with an optimism-corrected area under the receiver operating characteristic curve of 0.73 in development and 0.63 in external validation. PRS models showed limited external generalisability and did not improve prediction. Machine learning algorithms offered no advantage over regression models. Conclusions: A simple, interpretable logistic regression model based on routine clinical and cognitive variables can predict early recovery in FEP with acceptable generalisability. These findings support the use of transparent, clinically grounded models in early psychosis care and highlight the current limitations of genetic predictors for individualised treatment.
- 23 March 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-12
Open AccessPredicting early clinical recovery in first-episode psychosis: development and external validation of a clinically interpretable multivariable model
Background: Identifying patients with first-episode psychosis (FEP) who are unlikely to achieve early clinical recovery (ECR) is critical for personalised intervention and resource allocation. ECR – defined as the concurrent achievement of symptomatic and functional remission – represents a clinically meaningful outcome that captures both illness control and functional reintegration. Aims: To develop and externally validate prediction models for ECR using clinical, cognitive and genetic data. Method: We analysed two large, independent Spanish cohorts: the primeros episodios psicóticos cohort ( N = 335), for model development and internal validation, and the Programa Asistencial a las Fases Iniciales de Psicosis cohort ( N = 668), for external validation. Forty-seven baseline clinical and cognitive variables and 87 polygenic risk scores (PRSs) were examined. Predictors were selected using penalised logistic regression. Logistic regression and three machine learning algorithms were compared for discrimination, calibration and clinical utility. Results: The best-performing model was a logistic regression using six routinely collected clinical and cognitive predictors (duration of untreated psychosis, days of treated psychosis, baseline functioning, insight, executive function and cognitive reserve), with an optimism-corrected area under the receiver operating characteristic curve of 0.73 in development and 0.63 in external validation. PRS models showed limited external generalisability and did not improve prediction. Machine learning algorithms offered no advantage over regression models. Conclusions: A simple, interpretable logistic regression model based on routine clinical and cognitive variables can predict early recovery in FEP with acceptable generalisability. These findings support the use of transparent, clinically grounded models in early psychosis care and highlight the current limitations of genetic predictors for individualised treatment.
- Open Access
- 23 March 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 146, 111675
Polygenic contributions to brain cortical measures, subcortical volumes and hippocampal subfields in first episode psychosis
- 23 March 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 146, 111675
Open AccessPolygenic contributions to brain cortical measures, subcortical volumes and hippocampal subfields in first episode psychosis
- Open Access
- 31 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-7
Association of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with clozapine treatment in schizophrenia
Gene expression profiling studies could be a valuable tool in identifying the specific genes and pathways involved in the mechanism of action of clozapine, leading to a better understanding of the molecular biology underlying treatment-resistant schizophrenia (TRS). We aimed to identify the co-expressed modules that reflect the genetic differences between clozapine-treated and non-clozapine-treated patients with schizophrenia as a proxy of TRS. Gene expression of DLPFC samples from 26 subjects with schizophrenia (13 clozapine treated and 13 non-clozapine treated) were analyzed using Clariom S Human Array. Weighted gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its association with clozapine treatment. As a result of our analysis of the gene co-expression architecture in the DLPFC, among the 13 modules identified, one module (green) was significantly associated with clozapine treatment (p = 3.7 × 10−2). This module was significantly enriched in astrocyte markers (5.7 × 10−29) and genes involved in the polygenic architecture of TRS (1.6 × 10−2). This finding provides cell type-specific associations that could help in the interpretation of the neurobiological basis of TRS. A better understanding of the specific DLPFC cell types involved in clozapine treatment will contribute to the study of potential pathways and ultimately help improve psychiatric classification tools in personalized medicine.
- 31 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-7
Open AccessAssociation of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with clozapine treatment in schizophrenia
Gene expression profiling studies could be a valuable tool in identifying the specific genes and pathways involved in the mechanism of action of clozapine, leading to a better understanding of the molecular biology underlying treatment-resistant schizophrenia (TRS). We aimed to identify the co-expressed modules that reflect the genetic differences between clozapine-treated and non-clozapine-treated patients with schizophrenia as a proxy of TRS. Gene expression of DLPFC samples from 26 subjects with schizophrenia (13 clozapine treated and 13 non-clozapine treated) were analyzed using Clariom S Human Array. Weighted gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its association with clozapine treatment. As a result of our analysis of the gene co-expression architecture in the DLPFC, among the 13 modules identified, one module (green) was significantly associated with clozapine treatment (p = 3.7 × 10−2). This module was significantly enriched in astrocyte markers (5.7 × 10−29) and genes involved in the polygenic architecture of TRS (1.6 × 10−2). This finding provides cell type-specific associations that could help in the interpretation of the neurobiological basis of TRS. A better understanding of the specific DLPFC cell types involved in clozapine treatment will contribute to the study of potential pathways and ultimately help improve psychiatric classification tools in personalized medicine.
- Open Access
- 15 February 2025
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 94, 4-15
Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia
- 15 February 2025
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 94, 4-15
Open AccessMethylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia
- Open Access
- 14 January 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-14
Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.
- 14 January 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-14
Open AccessEffectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.